MDVL · Medavail Holdings, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | $43.11M | $22.13M | $13.97M | $1.03M | $526.0K | $526.0K |
| Cost of Revenue | $40.52M | $21.81M | $8.80M | $397.0K | $248.0K | $308.0K |
| Gross Profit | $2.58M | $317.0K | $5.16M | $635.0K | $112.0K | $218.0K |
| R&D | $1.11M | $849.0K | $682.0K | $417.0K | $417.0K | $46.0K |
| SG&A | $23.50M | $22.28M | $16.56M | $1.68M | $1.83M | $2.01M |
| Total Operating Expenses | $49.01M | $30.66M | - | $4.85M | $4.44M | $4.29M |
| D&A | $1.21M | $1.17M | $1.02M | $52.0K | $35.0K | - |
| Operating Income | ($46.42M) | ($43.51M) | ($25.50M) | ($4.22M) | ($4.33M) | ($4.07M) |
| Interest Expense | $1.17M | $589.0K | $1.24M | $40.0K | $16.0K | $2.0K |
| Income Tax | $24.0K | $2.0K | $0 | - | ($1.12M) | - |
| Net Income | ($47.62M) | ($43.81M) | ($26.81M) | ($4.26M) | ($3.22M) | ($4.06M) |
| EPS - Basic | ($0.72) | ($1.34) | ($4.69) | - | - | - |
| EPS - Diluted | ($0.72) | ($1.34) | ($4.69) | - | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $11.44M | $19.69M | $57.94M | $64.0K | $15.0K | $923.0K |
| Accounts Receivable | $2.21M | $1.19M | $1.52M | $5.0K | $78.0K | $4.0K |
| Inventory | $6.94M | $3.92M | $2.82M | $1.67M | $1.68M | $1.78M |
| Accounts Payable | $1.68M | $4.01M | $409.0K | $277.0K | $236.0K | $176.0K |
| Current Assets | $23.93M | $27.39M | $63.87M | $1.76M | $2.90M | $2.87M |
| Total Assets | $33.13M | $38.14M | $69.33M | $3.04M | $4.46M | $4.79M |
| Current Liabilities | $5.94M | $7.50M | $7.61M | $1.71M | $1.63M | $431.0K |
| Long-term Debt | $4.80M | $9.54M | $12.48M | - | - | - |
| Total Liabilities | $12.31M | $19.07M | $8.26M | $1.86M | $1.63M | $431.0K |
| Stockholders' Equity | $20.82M | $19.07M | $61.07M | $1.18M | $2.82M | $4.36M |
| Retained Earnings | ($239.71M) | ($192.09M) | ($148.28M) | ($39.33M) | ($35.07M) | ($31.84M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($47.66M) | ($42.52M) | ($28.63M) | ($2.37M) | ($3.25M) | ($3.78M) |
| Investing Cash Flow | ($2.27M) | ($3.31M) | ($817.0K) | - | - | ($2.0K) |
| Financing Cash Flow | $41.97M | $7.93M | $78.60M | $2.42M | $2.34M | $2.84M |
| CapEx | $1.22M | $841.0K | $662.0K | - | $2.0K | $2.0K |
| Free Cash Flow | ($48.88M) | ($43.36M) | ($29.30M) | - | ($3.25M) | ($3.79M) |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 6.0% | 1.4% | 37.0% | 61.5% | 21.3% | 41.4% |
| Operating margin | -107.7% | -196.6% | -182.6% | -408.7% | -823.0% | -773.4% |
| EBITDA margin | -104.9% | -191.3% | -175.3% | -403.7% | -816.3% | - |
| Net margin | -110.5% | -198.0% | -191.9% | -412.6% | -612.7% | -771.5% |
| Free cash flow margin | -113.4% | -195.9% | -209.7% | - | -618.3% | -719.6% |
| FCF / Net income | 1.03 | 0.99 | 1.09 | - | 1.01 | 0.93 |
| R&D / Revenue | 2.6% | 3.8% | 4.9% | 40.4% | 79.3% | 8.7% |
| SG&A / Revenue | 54.5% | 100.7% | 118.6% | 162.8% | 347.7% | 382.9% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -143.7% | -114.9% | -38.7% | -140.2% | -72.3% | -84.6% |
| Return on equity | -228.7% | -229.7% | -43.9% | -360.8% | -114.3% | -93.0% |
| Return on invested capital | -143.1% | -120.1% | -27.4% | - | - | - |
| Liquidity | ||||||
| Current ratio | 4.03 | 3.65 | 8.39 | 1.03 | 1.78 | 6.66 |
| Quick ratio | 2.86 | 3.13 | 8.02 | 0.05 | 0.75 | 2.53 |
| Cash ratio | 1.93 | 2.62 | 7.61 | 0.04 | 0.01 | 2.14 |
| Leverage | ||||||
| Debt / Equity | 0.23 | 0.50 | 0.20 | - | - | - |
| Debt / Assets | 0.14 | 0.25 | 0.18 | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -39.6x | -73.9x | -20.5x | -105.5x | -270.6x | -2034.0x |
| Equity multiplier | 1.59 | 2.00 | 1.14 | 2.57 | 1.58 | 1.10 |
| Liabilities / Assets | 0.37 | 0.50 | 0.12 | 0.61 | 0.37 | 0.09 |
| Efficiency | ||||||
| Asset turnover | 1.30 | 0.58 | 0.20 | 0.34 | 0.12 | 0.11 |
| Inventory turnover | 5.84 | 5.57 | 3.13 | 0.24 | 0.15 | 0.17 |
| Days sales outstanding | 19d | 20d | 40d | 2d | 54d | 3d |
| Days inventory outstanding | 62d | 66d | 117d | 1532d | 2467d | 2108d |
| Days payable outstanding | 15d | 67d | 17d | 255d | 347d | 209d |
| Cash conversion cycle | 66d | 18d | 140d | 1279d | 2173d | 1902d |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 94.8% | 58.4% | 1253.5% | 96.2% | 0.0% | 60.9% |
| Revenue CAGR (3y) | 247.0% | 247.8% | 198.3% | 46.7% | 49.0% | -59.1% |
| Revenue CAGR (5y) | 141.4% | 132.3% | 144.8% | -33.0% | -34.4% | -12.3% |
| Gross profit growth (YoY) | 715.5% | -93.9% | 713.1% | 467.0% | -48.6% | 2625.0% |
| Operating income growth (YoY) | -6.7% | -70.6% | -504.6% | 2.6% | -6.4% | 5.5% |
| Net income growth (YoY) | -8.7% | -63.4% | -529.6% | -32.1% | 20.6% | 6.5% |
| EPS growth (YoY) | 46.3% | 71.4% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -12.7% | -48.0% | - | - | 14.1% | -3.0% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 9.2% | -68.8% | 5075.2% | -58.2% | -35.4% | -17.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Business segments
$22.13M totalRetail Pharmacy Services Segment$20.20M · 91.3%
Pharmacy Technology Segment$1.93M · 8.7%
Product / service
$44.21M totalPharmacy And Hardware$21.12M · 47.8%
Retail Pharmacy$20.20M · 45.7%
Service$1.01M · 2.3%
Professional Services$551.0K · 1.2%
Hardware$470.0K · 1.1%
Subscription$400.0K · 0.9%
Software$259.0K · 0.6%
Maintenance And Support$161.0K · 0.4%
Installation$39.0K · 0.1%
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
-8.08
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
4/9
Neutral
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✗Cash flow > net income
- ✓Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Retail-Drug Stores and Proprietary Stores
Comparing MedAvail Holdings against the 5 most active filers in the same SIC group.